Revolution Medicines, Inc.
RVMDDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
14wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Gemcitabine
Pancreatic Cancer
daraxonrasib
NSCLC (Non-small Cell Lung Cancer)
RMC-6236
Colorectal Cancer
RMC-4630
Non-Small Cell Lung Cancer
RMC-6291
Non-Small Cell Lung Cancer, NSCLC
Cobimetinib
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gemcitabine | Phase 3 | Pancreatic Cancer | - | - |
daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | - | - |
RMC-6236 | Phase 3 | Colorectal Cancer | - | - |
RMC-4630 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC | - | - |
Cobimetinib | Phase 2 | Solid Tumor | - | - |
Colorectal Cancer
1 drug in this indication
Non-Small Cell Lung Cancer, NSCLC
1 drug in this indication
Solid Tumor
1 drug in this indication
Pancreatic Cancer
1 drug in this indication
NSCLC (Non-small Cell Lung Cancer)
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)